Re-reading Dr. Yang's paper clearly suggests RO wo

Re-reading Dr. Yang's paper clearly suggests RO would have been a very important piece of data to have indeed.

"Interestingly, our data suggest that the current leronlimab dosing regimen may be suboptimal, since several patients exhibited rapid drops in the inflammatory marker CRP only after the second dose. Given its estimated half-life of about 10 days, the second dose after 7 days should achieve a higher peak than the first dose, and the maximal effect would not be achieved until after the second dose. This is consistent with the receptor occupancy data presented by Patterson et al [14], showing maximal effect after the second dose of the same regimen."

"It was also notable that clinical responsiveness to treatment was highly variable; some patients appeared to have a rapid dramatic response to treatment (eg, participants A and F who were rapidly extubated after being on ventilators and participants B, C, and D who were weaned off supplemental oxygen and discharged home within 3 days), while others seemed to have less effect. Mechanistic studies may uncover determinants and markers for leronlimab responsiveness, such as CCR5 occupancy [14]. Controlled trials will be required to assess the benefit of treatment."

"Randomized, placebo-controlled trials are now underway and should help provide more helpful data to clarify efficacy and predictors of response to leronlimab when treating COVID-19."